Table 2.
Immune checkpoint inhibitor efficacy outcomes in various molecular alterations
| Driver | n | Best response (%) | PFS | OS | ||||
| CR/PR | SD | PD | Median (months) | 6 month PFS (%) | 1 year PFS (%) | Median (months) | ||
| BRAF | 38 | 28.1 | 28.1 | 43.8 | 3 | 35 | 19 | 13.6 |
| KRAS | 252 | 27.2 | 23.1 | 49.8 | 3.2 | 39 | 26 | 13.5 |
| ROS1 | 5 | 20 | 0 | 80 | NA | NA | NA | NA |
| MET | 36 | 15.6 | 34.4 | 50 | 3.4 | 33 | 23 | 18.4 |
| EGFR | 110 | 11 | 18 | 71 | 2 | 16 | 6 | 8.8 |
| HER2 | 23 | 9.5 | 28.6 | 61.9 | 3.5 | 34 | 17 | 10 |
| RET | 14 | 7.1 | 21.4 | 71.4 | 2.2 | 16 | 8 | 6.5 |
| ALK | 18 | 0 | 21.4 | 78.6 | 2.1 | 16 | 8 | 17 |
Reprinted with permission from American Society of Clinical Oncology. Copyright 2018. All rights reserved. Mazieres J, Drilon AE, Mhanna LJ et al. Efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients harbouring activating molecular alterations (ImmunoTarget). J Clin Oncol 2018; 36, suppl:abstr 9010.
CR, complete response; NA, not available; PFS, progression-free survival; PR, partial response.